Aldosterone Inhibition and Cardiovascular Protection: More Important Than it Once Appeared (Q28289525)

https://api.crossref.org/works/10.1007/S10557-010-6256-6

14 June 2024

1 reference

Felipe A. Martinez

1

1 reference

Europe PubMed Central

PubMed publication ID

20676926

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20676926

full work available at URL

14 June 2024

language of work or name

English

0 references

publication date

August 2010

0 references

http://link.springer.com/content/pdf/10.1007/s10557-010-6256-6.pdf

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

http://link.springer.com/article/10.1007/s10557-010-6256-6/fulltext.html

14 June 2024

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

http://link.springer.com/content/pdf/10.1007/s10557-010-6256-6

14 June 2024

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Cardiovascular Drugs and Therapy

14 June 2024

published in

0 references

volume

24

0 references

issue

4

0 references

page(s)

345-50

0 references

cites work

Association Between Increased Plasma Levels of Aldosterone and Decreased Systemic Arterial Compliance in Subjects With Essential Hypertension

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways.

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1161/01.CIR.0000135599.33787.CA

New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study

2

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Mineralocorticoid receptor antagonism in experimental atherosclerosis

14 June 2024

4

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Increased NADH-Oxidase–Mediated Superoxide Production in the Early Stages of Atherosclerosis

14 June 2024

5

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation

14 June 2024

7

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response

14 June 2024

8

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension

14 June 2024

9

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts

14 June 2024

10

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids.

14 June 2024

11

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation

14 June 2024

12

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension

14 June 2024

13

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Remodeling of the rat right and left ventricles in experimental hypertension

14 June 2024

15

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension

14 June 2024

16

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients

14 June 2024

17

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Prevalence and characteristics of the metabolic syndrome in primary aldosteronism

14 June 2024

19

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation

14 June 2024

20

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells

14 June 2024

21

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Biomarkers of vascular disease linking inflammation to endothelial activation: Part II.

14 June 2024

22

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts

14 June 2024

23

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Serum aldosterone and the incidence of hypertension in nonhypertensive persons

14 June 2024

24

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

14 June 2024

25

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

14 June 2024

26

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

14 June 2024

27

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

14 June 2024

28

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension

14 June 2024

29

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study

14 June 2024

30

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

14 June 2024

31

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure

14 June 2024

32

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise th

14 June 2024

33

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice

14 June 2024

34

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension

14 June 2024

35

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy

14 June 2024

36

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Usefulness of spironolactone in a specialized heart failure clinic

14 June 2024

37

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Revista argentina de cardiologia

14 June 2024

38

74

389

F Martinez

2006

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

14 June 2024

39

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure

14 June 2024

40

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

14 June 2024

41

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction

14 June 2024

44

1 reference

https://api.crossref.org/works/10.1007/S10557-010-6256-6

14 June 2024

Identifiers